State Street’s Unicycive Therapeutics UNCY Stock Holding History

State Street’s Portfolio UNCY Stock Details UNCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.11M	Buy	450,162 +370,135	+463%	+$2.73M	﹤0.01%	3320
2026 Q1	$527K	Buy	80,027 +14,800	+23%	+$97K	﹤0.01%	3644
2025 Q4	$376K	Buy	65,227 +10,400	+19%	+$55.5K	﹤0.01%	3751
2025 Q3	$239K	Buy	54,827 +42,304	+338%	+$184K	﹤0.01%	3862
2025 Q2	$59.7K	Sell	12,523 -1	-0%	-$6	﹤0.01%	4067
2025 Q1	$72K	Hold	12,524	–	–	﹤0.01%	4035
2024 Q4	$99.5K	Buy	12,524 +8,130	+185%	+$45K	﹤0.01%	3991
2024 Q3	$17.9K	Hold	4,394	–	–	﹤0.01%	4234
2024 Q2	$22K	Buy	4,394 +890	+25%	+$8.75K	﹤0.01%	4268
2024 Q1	$48.4K	Hold	3,504	–	–	﹤0.01%	4169
2023 Q4	$30.4K	Hold	3,504	–	–	﹤0.01%	4281
2023 Q3	$30.1K	Hold	3,504	–	–	﹤0.01%	4378
2023 Q2	$44.8K	Hold	3,504	–	–	﹤0.01%	4445
2023 Q1	$73.6K	Buy	+3,504	New	+$34.9K	﹤0.01%	4410

Other funds holding UNCY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

State Street's UNCY Position: Q2 2026 in Review

State Street increased its Unicycive Therapeutics (UNCY) stake by 463% in Q2 2026, buying an estimated $2.73M and bringing the position to 450,162 shares worth $2.11M. The position accounts for ﹤0.01% of the portfolio, ranked #3320.

State Street first reported a position in UNCY in Q1 2023 and has held it in 14 quarters since. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

State Street held 450,162 shares of Unicycive Therapeutics worth $2.11M as of Q2 2026.
State Street bought 370,135 Unicycive Therapeutics shares in Q2 2026, an estimated $2.73M.
Unicycive Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3320 holding.
State Street first reported a position in Unicycive Therapeutics in Q1 2023 and has held it in 14 quarters since.
80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.